Will the launch of Favipiravir mark the turnaround for Glenmark Pharma?

If the drug proves to be efficacious for Covid treatment, Glenmark
will enjoy first mover advantage.

https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/will-the-launch-of-favipiravir-mark-the-turnaround-for-glenmark-pharma/articleshow/76498905.cms

Comments

Popular posts from this blog

Biotecnika Times Newsletter 25.10.2021 Tata Innovation Fellowship 2021, NCCS PhD Admission

Biotecnika Times Newsletter 29.11.2021 NABI Research Training, National Cancer Tissue

Biotecnika Times – Newsletter 25.01.2021 – CSIR Notice, CSIR-CCMB & ILS Hiring, FSSAI Funded